Clinical Trial Update: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ONC-392 in combination with Lutetium-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (phase 1/2, currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium Lu-177 Vipivotide Tetraxetan (Lutetium-177 vipivotide tetraxetan)
• ONC-392

Snippet

Sponsor: OncoC4, Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING